Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01061112 · ClinicalTrials.gov registry record
Effects of Genotype on CYP2C9 Drug Interactions
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 23
- Enrollment target
NCT01061112: Completed study, sponsored by University of Minnesota.
NCT01061112 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01061112 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
This research study will help determine how a person's genetic makeup affects their responses to drugs, the ability of the body to break down drugs, and their potential to experience an interaction between drugs. We are investigating the drug interactions between an antifungal drug called fluconazole and the commonly used drugs tolbutamide, flurbiprofen, and ketoprofen. Tolbutamide is used for management of Type 2 diabetes. Both flurbiprofen and ketoprofen are non-steroidal anti-inflammatory drugs (NSAIDs) often used for arthritis or pain. We are interested in studying whether individuals with certain genetic profiles have different drug interactions than normal. This research is being done to see if certain genetic profiles require us to adjust medication doses differently than is needed for the general population. Genetic profiles of subjects are determined from their previous participation in the Pharmacogenetics Registry (Investigator Richard Brundage, University of Minnesota). The study hypothesis is: Fraction metabolized by CYP2C9 enzyme determines the extent of drug interactions in CYP2C9\*1/\*1 individuals but this factor (fraction metabolized) becomes less influential and drug interactions are attenuated in a gene-dose dependent manner in individuals with one or more defective alleles.
Primary Outcome
Measure of blood concentrations of Flurbiprofen 48 hours post Flurbiprofen dose
Interventions
- DRUG Flurbiprofen Control - Flurbiprofen Only
- DRUG Flurbiprofen Inhibition - Flurbiprofen & Fluconazole
- DRUG Ketoprofen Control - Ketoprofen Only
- DRUG Ketoprofen Inhibition - Ketoprofen & Fluconazole
- DRUG Tolbutamide Control - Tolbutamide Only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2009-12 |
| Est. Completion | 2014-06 |
What the finished NCT01061112 record still lists
NCT01061112 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 0 conditions, and to 5 interventions - of which Flurbiprofen Control - Flurbiprofen Only is the first listed.
NCT01061112 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01061112 about?
NCT01061112 is a clinical study titled "Effects of Genotype on CYP2C9 Drug Interactions". This research study will help determine how a person's genetic makeup affects their responses to drugs, the ability of the body to break down drugs, and their potential to experience an interaction between drugs. We are investigating the drug interactions between an antifungal drug called fluconazol...
What is the current status of trial NCT01061112?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2009-12. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01061112?
The interventions under investigation include: Flurbiprofen Control - Flurbiprofen Only (DRUG), Flurbiprofen Inhibition - Flurbiprofen & Fluconazole (DRUG), Ketoprofen Control - Ketoprofen Only (DRUG), Ketoprofen Inhibition - Ketoprofen & Fluconazole (DRUG), Tolbutamide Control - Tolbutamide Only (DRUG).
Who is sponsoring clinical trial NCT01061112?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia